Search results
Results from the WOW.Com Content Network
AbbVie has retained most of the U.S. market for Humira this year, despite the launch of 10 biosimilar alternatives to the drug since January 2023 from companies including Pfizer.
Despite steep discounts in pricing — 5% to up to 90% of Humira's list price — AbbVie remained in the lead with a 96% market share. That's based on data from biopharma Samsung Bioepis in April.
Humira was once the world's biggest selling prescription medicine with peak sales of $21.2 billion in 2022. Express Scripts and UnitedHealth Group's Optum Rx - two of the largest PBMs - chose to ...
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
The annual cost of the biosimilar, branded as Yusimry, will be around $13,000, compared with $90,000 for Humira, Coherus said. Coherus has also partnered with Billionaire entrepreneur Mark Cuban's ...
(Reuters) -Cigna Group's Express Scripts pharmacy benefits unit will add three biosimilar versions of AbbVie's blockbuster arthritis treatment Humira to its list of preferred drugs, the company ...
Humira cost the U.S. government more than $2.9 billion in 2021, according to data from the agency that runs the Medicare and Medicaid health programs. It is expected to be excluded from government ...
For premium support please call: 800-290-4726 more ways to reach us